UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
|
|
|
|
|
Date of Report (Date of earliest event reported):
|
|
|
|
June 29, 2006 |
Aetna Inc.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Pennsylvania
|
|
1-16095
|
|
23-2229683 |
(State or other jurisdiction of
|
|
(Commission
|
|
(I.R.S. Employer |
incorporation)
|
|
File Number)
|
|
Identification No.) |
|
|
|
|
|
151 Farmington Avenue, Hartford, CT
|
|
|
|
06156 |
(Address of principal executive offices)
|
|
|
|
(Zip Code) |
|
|
|
|
|
Registrants telephone number, including area code:
|
|
|
|
(860) 273-0123 |
|
|
|
|
|
Former name or former address, if changed since last report:
|
|
|
|
Not applicable |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions:
o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b)) |
|
o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c)) |
TABLE OF CONTENTS
Section 7 Regulation FD
Item 7.01 Regulation FD Disclosure.
At meetings or in other conversations with analysts or investors, Aetna Inc.s (Aetnas)
management has recently reiterated its publicly disclosed operating earnings per share guidance of
$0.63 per share1 for the second
quarter 2006, and stated that it expects Aetnas Commercial Risk medical
cost ratio (MCR) for the second quarter to increase from
the first quarter, and that this MCR is
expected to subsequently decrease during the second half of the year. Aetnas management will also
reiterate these points in conversations during the remainder of June
2006.
1 Projected operating earnings per share exclude projected net realized capital
gains or losses. In addition, projected operating earnings per share exclude a $47 million after
tax charge for the write off of an insurance recoverable receivable in connection with a trial
court summary judgment ruling, an $8 million after tax net charge from the write off of debt
issuance costs and the recognition of a deferred gain on an interest rate swap in connection with
the redemption of its Senior Notes due 2041 and the offering and sale of its Senior Notes reported
by Aetna in its Current Reports on Form 8-K filed on May 9, 2006, May 18, 2006 and June 9, 2006,
respectively. Aetna is not able to project the amount of future net realized capital gains or
losses and other items and therefore cannot reconcile projected second quarter 2006 operating
earnings per share to projected income from continuing operations per share. Projected operating
earnings per share for the second quarter 2006 assume approximately 592 million weighted-average
diluted shares. Projected operating earnings per share for second quarter 2006 include the effect
of expensing stock-based compensation pursuant to Statement of Financial Accounting Standards No.
123 Revised, Share-Based Payment and reflect the effect of the February 17, 2006 two-for-one
stock split.
ADDITIONAL INFORMATION; CAUTIONARY STATEMENT The projections contained herein are forward
looking. Forward-looking information is based on managements estimates, assumptions and
projections, and is subject to significant uncertainties and other factors, many of which are
beyond Aetnas control. Important risk factors could cause actual future results and other future
events to differ materially from those currently estimated by management. Those risk factors
include, but are not limited to: unanticipated increases in medical costs (including increased
medical utilization, increased pharmacy costs, increases resulting from unfavorable changes in
contracting or re-contracting with providers, changes in membership mix to lower-premium or
higher-cost products or membership-adverse selection; as well as changes in medical cost estimates
due to the necessary extensive judgment that is used in the medical cost estimation process, the
considerable variability inherent in such estimates, and the sensitivity of such estimates to
changes in medical claims payment patterns and changes in medical cost trends); decreases in
membership or failure to achieve desired membership growth due to significant competition,
reputational issues or other factors; increases in medical costs or Group Insurance claims
resulting from any acts of terrorism, epidemics or other extreme events; the ability to reduce
administrative expenses while maintaining targeted levels of service and operating performance, and
to improve relations with providers while taking actions to reduce medical costs; the ability to
successfully implement Aetnas operating model to a projected growing membership base and to
successfully implement multiple strategic and operational initiatives simultaneously; lower levels
of investment income from continued low interest rates; adverse government regulation (including
legislative proposals eliminating or reducing ERISA pre-emption of state laws that would increase
potential litigation exposure, and other proposals, such as patients rights legislation, that
would increase potential litigation exposure or mandate coverage of certain health benefits);
adverse pricing actions by government payors; changes in size, product mix and medical cost
experience of membership in key markets; our ability to integrate, simplify, and enhance our
existing information technology system and platform to keep pace with changing customer and
regulatory needs; and the outcome of various litigation and regulatory matters, including
litigation and ongoing reviews of business practices by various regulatory authorities (including
the current industry wide investigation into insurance brokerage practices concerning broker
compensation arrangements, bid quoting practices and potential antitrust violations being conducted
by the New York Attorney General, the Connecticut Attorney General, and others, and for which Aetna
has received and may receive subpoenas, and may be subject to related litigation). For more
discussion of important risk factors that may materially affect Aetna, please see the risk factors
contained in Aetnas 2005 Annual Report on Form 10-K, on file with the Securities and Exchange
Commission. You also should read Aetnas 2005 Annual Report on Form 10-K and 2006 first quarter
report on Form 10-Q on file with the Securities and Exchange Commission for a discussion of Aetnas
historical results of operations and financial condition.
None of the information furnished in this report shall be deemed to be filed for purposes of
Section 18 of the Securities Exchange Act of 1934, as amended. None of the information furnished in
this report shall be incorporated by reference in any filing under the Securities Act of 1933, as
amended.